基于人工智能决策支持改善头颈部放疗计划质量的前瞻性研究
该前瞻性研究将基于人工智能的决策支持工具(DST)纳入头颈部癌症容积调强弧形治疗(VMAT)临床流程,对50例连续患者比较医师指令、AI指令及混合指令对危及器官(OAR)剂量的影响。结果显示混合指令在多数OAR上降低剂量目标超过3 Gy,临床计划平均剂量较医师指令降低4.3–16 Gy、较AI指令降低5.6–9.1 Gy,且多数OAR剂量指标优于机构历史计划并满足全部NRG约束。
要点
- AI决策支持工具可预估OAR剂量,与医师指令取较低值形成混合指令。
- 混合指令使22%–75%的OAR剂量目标降低超过3 Gy(临床显著阈值)。
- 临床计划平均剂量较医师指令降低4.3–16 Gy,较AI指令降低5.6–9.1 Gy。
核心结论
- AI决策支持工具可显著改善头颈部患者所有OAR的治疗指令,医师指令或AI指令单独均不足以最优指导计划设计。
研究设计与样本
- 前瞻性研究,DST剂量预测模型基于276份机构VMAT计划构建。
- 在IRB批准的前瞻性试验下,对50例连续患者依次生成医师指令(PD)和AI指令(AD),取较低者形成混合指令(HD)。
- 最终计划指标与各指令进行比较,剂量差异3 Gy视为临床显著。
主要发现
- 与AD和PD相比,HD在22%至75%的病例中使OAR剂量目标降低超过3 Gy(取决于OAR)。
- 临床计划通常满足这些更低约束,平均剂量较PD降低4.3至16 Gy,较AD单独降低5.6至9.1 Gy。
- 采用HD达到的剂量指标对大多数OAR显著优于机构历史计划,并对所有OAR满足NRG约束。
关键数值与推荐
- 剂量差异3 Gy被视为临床显著。
- HD使OAR剂量目标降低超过3 Gy的病例比例为22%至75%。
- 平均剂量降低:较PD为4.3至16 Gy,较AD为5.6至9.1 Gy。
临床怎么用
- 在头颈部VMAT计划设计中,可引入AI决策支持工具预估OAR剂量,与医师指令取较低值形成混合指令以改善OAR保护。
- 医师指令或AI指令单独使用均不足以最优指导计划,建议联合使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Volumetric modulated arc therapy (VMAT) planning for head and neck cancer is a complex process. While the lowest achievable dose for each individual organ-at-risk (OAR) is unknown a priori, artificial intelligence (AI) holds promise as a tool to accurately estimate the expected dose distribution for OARs. We prospectively investigated the benefits of incorporating an AI-based decision support tool (DST) into the clinical workflow to improve OAR sparing. MATERIALS AND METHODS: The DST dose prediction model was based on 276 institutional VMAT plans. Under an IRB-approved prospective trial, the physician first generated a custom OAR directive for 50 consecutive patients (physician directive, PD). The DST then estimated OAR doses (AI directive, AD). For each OAR, the treating physician used the lower directive to form a hybrid directive (HD). The final plan metrics were compared to each directive. A dose difference of 3 Gray (Gy) was considered clinically significant. RESULTS: Compared to the AD and PD, the HD reduced OAR dose objectives by more than 3 Gy in 22% to 75% of cases, depending on OAR. The resulting clinical plan typically met these lower constraints and achieved mean dose reductions between 4.3 and 16 Gy over the PD, and 5.6 to 9.1 Gy over the AD alone. Dose metrics achieved using the HD were significantly better than institutional historical plans for most OARs and NRG constraints for all OARs. CONCLUSIONS: The DST facilitated a significantly improved treatment directive across all OARs for this generalized H&N patient cohort, with neither the AD nor PD alone sufficient to optimally direct planning.
引用
- Sher DJ, Godley A, Park Y, et al. Prospective study of artificial intelligence-based decision support to improve head and neck radiotherapy plan quality. Clin Transl Radiat Oncol. 2021. PMID: 34159264. doi:10.1016/j.ctro.2021.05.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。